Crescent Biopharma
CBIO
32 hedge funds and large institutions have $114M invested in Crescent Biopharma in 2014 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 15 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 36 → 32 (-4)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
50% less capital invested
Capital invested by funds: $230M → $114M (-$116M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.77M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$432K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$343K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$336K |
| 5 |
MSA
Mason Street Advisors
Milwaukee,
Wisconsin
|
+$240K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.96M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.76M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.73M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.18M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$1.06M |
CBIO Hedge Fund Activity: Q2 2014 in Review
32 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2014, worth a combined $114M — down 50% from $230M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of CBIO and 11 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Franklin Resources, adding an estimated $1.77M. The largest seller was BlackRock Fund Advisors, cutting an estimated $1.96M.
- 32 institutional investors held Crescent Biopharma (CBIO) as of Q2 2014, down from 36 in Q1 2014.
- Funds reported $114M of Crescent Biopharma stock for Q2 2014, down 50% quarter-over-quarter.
- 11 funds opened new Crescent Biopharma positions in Q2 2014 and 15 closed out, a net change of -4 holders.
- The largest Crescent Biopharma buyer in Q2 2014 was Franklin Resources, an estimated $1.77M added.
- The largest Crescent Biopharma seller in Q2 2014 was BlackRock Fund Advisors, an estimated $1.96M sold.
Based on aggregated 13F filings for Q2 2014.